The First Symposium of Clinical Trials on Alzheimer's Diseases was successfully held in Shanghai- Press Release-Green Valley

Press Releases

News Reports

Press Releases

News Reports

The First Symposium of Clinical Trials on Alzheimer's Diseases was successfully held in Shanghai

Date：2015-03-15

On March 15, 2015, Green Valley Pharmaceutical Co., Ltd. and the Shanghai Institute of Materia Medica at Chinese Academy of Sciences hosted the first Symposium of Clinical Trials on Alzheimer's Disease (AD) of Shanghai in Kerry Hotel Pudong Shanghai.

The leading principal investigators (PI) in the phase III clinical study of the novel anti-AD drug GV-971 were Professor Zhang Zhenxin from the Peking Union Medical College Hospital and Professor Xiao Shifu from the Shanghai Mental Health Center, who are responsible for providing guidance and expertise on the clinical trial.

Four world-renowned American experts in AD research, including Professor Rachelle Doody from the Baylor College of Medicine, Professor Lon Schneider from the Keck School of Medicine at USC, Professor Jing Zhang from the University of Washington, and Dr. Roza Hayduk from Quintiles were invited to this symposium. The professors focused the academic discussions on the current status, problems and challenges of AD clinical research, as well as the frontiers and hotspots in the global progress of AD clinical diagnosis, AD pathological features, and AD neuroimaging analysis. They also answered questions posed by symposium participants.

ShareTo：